[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR055011A1 - Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco - Google Patents

Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco

Info

Publication number
AR055011A1
AR055011A1 ARP050105313A ARP050105313A AR055011A1 AR 055011 A1 AR055011 A1 AR 055011A1 AR P050105313 A ARP050105313 A AR P050105313A AR P050105313 A ARP050105313 A AR P050105313A AR 055011 A1 AR055011 A1 AR 055011A1
Authority
AR
Argentina
Prior art keywords
preparation
pharmaco
tetrahydroquinoline compound
composite
preparation process
Prior art date
Application number
ARP050105313A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR055011A1 publication Critical patent/AR055011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un procedimiento para su preparacion, así como su uso para la preparacion de fármacos, especialmente como inhibidor de la proteína de transferencia de éster de colesterol (CETP), son utiles para el tratamiento y/o la prevencion de enfermedades cardiovasculares, especialmente de hipolipoproteinemias, dislipidemias, hipertrigliceridemias, hiperlipidemias, hipercolesterolemias y arteriosclerosis. Reivindicacion 1: Compuesto de la formula (1), en la que R representa ciclopentilo o isopropilo, así como sus sales, solvatos y solvatos de las sales.
ARP050105313A 2004-12-18 2005-12-16 Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco AR055011A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
AR055011A1 true AR055011A1 (es) 2007-08-01

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105313A AR055011A1 (es) 2004-12-18 2005-12-16 Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco

Country Status (27)

Country Link
US (2) US8124775B2 (es)
EP (1) EP1828137B1 (es)
JP (1) JP5132317B2 (es)
KR (1) KR20070090248A (es)
AR (1) AR055011A1 (es)
AT (1) ATE555097T1 (es)
AU (1) AU2005315770B2 (es)
BR (1) BRPI0519602A2 (es)
CA (1) CA2591397A1 (es)
CU (1) CU23452B7 (es)
CY (1) CY1112887T1 (es)
DK (1) DK1828137T3 (es)
DO (1) DOP2005000259A (es)
ES (1) ES2384980T3 (es)
GT (1) GT200500377A (es)
IL (1) IL184008A (es)
MA (1) MA29100B1 (es)
MX (1) MX2007007188A (es)
NO (1) NO20073146L (es)
PE (1) PE20060767A1 (es)
PL (1) PL1828137T3 (es)
PT (1) PT1828137E (es)
RU (1) RU2393151C2 (es)
SI (1) SI1828137T1 (es)
TW (1) TW200635900A (es)
UY (1) UY29276A1 (es)
WO (1) WO2006063828A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
AU2009221179A1 (en) * 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2536733B1 (en) * 2010-02-19 2014-11-26 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
ES2543176T3 (es) 2010-07-09 2015-08-17 Daiichi Sankyo Company, Limited Compuesto de piridina sustituido
EP2675811A1 (en) 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013024130A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
EP2801574B1 (en) 2012-01-06 2016-07-27 Daiichi Sankyo Company, Limited Acid adduct salts of substituted pyridine compound as cholesteryl ester transfer protein (cetp) inhibitors
CN114381512A (zh) 2014-07-30 2022-04-22 豪夫迈·罗氏有限公司 预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.

Also Published As

Publication number Publication date
US20080255068A1 (en) 2008-10-16
NO20073146L (no) 2007-09-18
US20120142728A1 (en) 2012-06-07
IL184008A0 (en) 2007-10-31
RU2007127127A (ru) 2009-01-27
EP1828137B1 (de) 2012-04-25
AU2005315770A1 (en) 2006-06-22
JP2008524145A (ja) 2008-07-10
TW200635900A (en) 2006-10-16
BRPI0519602A2 (pt) 2009-02-25
DOP2005000259A (es) 2006-11-15
CA2591397A1 (en) 2006-06-22
AU2005315770B2 (en) 2011-12-08
KR20070090248A (ko) 2007-09-05
ATE555097T1 (de) 2012-05-15
PE20060767A1 (es) 2006-09-10
EP1828137A1 (de) 2007-09-05
IL184008A (en) 2012-03-29
CY1112887T1 (el) 2016-04-13
RU2393151C2 (ru) 2010-06-27
DK1828137T3 (da) 2012-07-23
MX2007007188A (es) 2007-08-14
PL1828137T3 (pl) 2012-09-28
US8124775B2 (en) 2012-02-28
GT200500377A (es) 2006-11-09
WO2006063828A1 (de) 2006-06-22
PT1828137E (pt) 2012-07-04
ES2384980T3 (es) 2012-07-16
JP5132317B2 (ja) 2013-01-30
UY29276A1 (es) 2006-07-31
SI1828137T1 (sl) 2012-08-31
CU23452B7 (es) 2009-12-01
MA29100B1 (fr) 2007-12-03

Similar Documents

Publication Publication Date Title
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
NO20065535L (no) Behandling av respiratorisk sykdom
BRPI0413490A (pt) novos compostos
PA8680701A1 (es) Derivados de oxindol
UY29876A1 (es) Derivados de acidos dicarboxilicos y su uso
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
BR0010555A (pt) Inibidores de neuraminidases
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
NO20016001D0 (no) Substituert fenylpropansyrederivater som agonister for human peroksisom proliferantaktivert reseptor (PPAR)<alfa>
CL2004000293A1 (es) Compuestos derivados de dihidrofenantridin-sulfonamidas sustituidas, sus sales; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y su uso en el tratamiento de la diabetes tipo ii, alzheimer, demencia senil, asma, col
CY1113494T1 (el) 8-ΕΤΕΡΟΑΡΥΛΟ-3-ΑΛΚΥΛΟ-1,3-ΔΙΥΔΡΟ-ΙΜΙΔΑΖΟ[4,5-c]ΚΙΝΟΛΙΝ-2-ΟΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ ΡΙ-3
ECSP088970A (es) Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
TW200833682A (en) Pharmaceutical compounds
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
AR053135A1 (es) Compuestos betamimeticos eficaces a largo plazo para el tratamiento de enfermedades respiratorias
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
AR055011A1 (es) Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
PA8572001A1 (es) Derivados de isoquinolina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal